RecruitingPhase 1NCT07508241

A Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or Obesity

A PHASE 1, OPEN-LABEL, MULTIPLE DOSE STUDY TO INVESTIGATE THE IMPACT OF PF 08653944 ON GASTRIC EMPTYING IN ADULT PARTICIPANTS WITH OVERWEIGHT OR OBESITY

Sponsor

Pfizer

Enrollment

20 participants

Start Date

Mar 31, 2026

Study Type

INTERVENTIONAL

Conditions

Obesity Overweight Drug Interaction Overweight and/or Obesity

Summary

This study looks at how a study medicine called PF-08653944 affects how quickly the stomach empties food after eating. It is being done in adults who are overweight or have obesity. Participants will receive the study medicine for a short period, and doctors will measure how the medicine moves through the stomach and monitor safety. The goal is to better understand how this medicine works in the body and to check for any side effects. The information from this study may help researchers plan future studies of this medicine.

Eligibility

Min Age: 18 YearsMax Age: 99 Years

Inclusion Criteria3

Adults ≥18 years at screening, male or female, generally healthy as determined by medical history, physical examination, laboratory tests, and ECG.
Body mass index (BMI) 27-45 kg/m² and body weight >50 kg (110 lb).
Participants with overweight or obesity

Exclusion Criteria4

History or presence of clinically significant medical conditions, including but not limited to:
Cardiovascular, hepatic, renal, pulmonary, endocrine, hematologic, neurologic, gastrointestinal (including pancreatitis or gallbladder disease), or significant psychiatric disorders.
Any form of diabetes, HbA1c ≥6.5%, or fasting plasma glucose ≥126 mg/dL.
Prior exposure to a GLP-1 receptor agonist within 90 days before first dose, or prior participation in a study with PF-08653944.

Interested in this trial?

Get notified about updates and connect with the research team.